Skip to main content

SABCS 2019: dati practice changing nel carcinoma mammario metastatico

By 12 Dicembre 2019Maggio 12th, 2021No Comments
Temi

Si prospettano cambiamenti significativi per il trattamento del carcinoma mammario metastatico HER2 positivo. I tre maggiori studi di SABCS 2019, commentati da Giuseppe Curigliano (Divisione Sviluppo di Nuovi Farmaci per Terapie Innovative, Istituto Europeo di Oncologia, Milano), che abbiamo incontrato a San Antonio.

BIBLIOGRAFIA

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator’s Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1 – DS8201-A-U301 (DESTINY-B02) https://bit.ly/2O8F4G9

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane – DS8201-A-U302 (DESTINY-B03) https://bit.ly/2qL5JRw

A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician’s Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects – DS8201-A-U303 https://bit.ly/2Kl7lZ8